ReviewOxidative medicine and cellular longevity2020
Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis.
Review in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 249 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
249 citing papers in PubMed, 3 syntheses or guidelines pooled it, 427 citations in OpenAlex.
- Immunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study.BMC cardiovascular disorders · 2025Pooled it
- A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction.Frontiers in immunology · 2024Pooled it
- Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- Effects of stannous fluoride dentifrice on gingival health and oxidative stress markers: a prospective clinical trial.BMC oral health · 2024Trial
- Cardiovascular Effects Associated with the Female Athlete Triad: Emerging Evidence Statement from the Female and Male Athlete Triad Coalition.Sports medicine (Auckland, N.Z.) · 2026Review
- Association between cerebrospinal fluid metabolites and ischemic stroke: a Mendelian randomization analysis.Journal of thrombosis and thrombolysis · 2026Article
- Screening of Anti-atherosclerosis Drugs Based on the Apolipoprotein apoeb Gene Knockout Zebrafish Model.Cardiovascular drugs and therapy · 2026Article
- Macrophage Differentiation Selectively Downregulates RPS15A While Preserving RPL13A and RPL17 Expression in THP-1-Derived Macrophages.Journal of cardiovascular development and disease · 2026Article
- Immunomodulatory roles of the HLA family and B2M in atherosclerosis: Diagnostic biomarkers and thrombosis risk.Medicine · 2026Article
- INO80E Suppresses Oxidized LDL-Induced Endothelial Apoptosis Through HDAC1-Mediated Stabilization of YY1.Biomolecules · 2026Article
- Freeze-DriedBiomolecules · 2026Article
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Review
- Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026Article
- Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Cholesterol-depleted macrophage membrane-coated nano-rapamycin for targeted atherosclerosis therapy.Journal of nanobiotechnology · 2026Article
- Association of the atherogenic index of plasma and its integrative novel adiposity-based composites with all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: novel adiposity-derived AIP indices provide modest incremental prognostic information.Cardiovascular diabetology · 2026Article
- Lipid-Induced Endothelial Dysfunction: Pro-Atherogenic Properties of Multinucleated Variant Endothelial Cells.International journal of molecular sciences · 2026Article
- Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies.Cardiovascular diabetology · 2026Article
- The synergistic pattern of metabolic-inflammatory changes jointly predicts cardiovascular risk in Chinese middle-aged and older adults: a prospective cohort study.Scientific reports · 2026Article
189 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidaemia has a prominent role in the onset of notorious atherosclerosis, a disease of medium to large arteries. Atherosclerosis is the prime root of cardiovascular events contributing to the most considerable number of morbidity and mortality worldwide. Factors like cellular senescence, genetics, clonal haematopoiesis, sedentary lifestyle-induced obesity, or diabetes mellitus upsurge the tendency of atherosclerosis and are foremost pioneers to definitive transience. Accumulation of oxidized low-density lipoproteins (Ox-LDLs) in the tunica intima triggers the onset of this disease. In the later period of progression, the build-up plaques rupture ensuing thrombosis (completely blocking the blood flow), causing myocardial infarction, stroke, and heart attack, all of which are common atherosclerotic cardiovascular events today. The underlying mechanism is very well elucidated in literature but the therapeutic measures remains to be unleashed. Researchers tussle to demonstrate a clear understanding of treating mechanisms. A century of research suggests that lowering LDL, statin-mediated treatment, HDL, and lipid-profile management should be of prime interest to retard atherosclerosis-induced deaths. We shall brief the Ox-LDL-induced atherogenic mechanism and the treating measures in line to impede the development and progression of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.